Cristian Luput Acquires 22,133 Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Cristian Luput acquired 22,133 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average cost of $2.51 per share, for a total transaction of $55,553.83. Following the acquisition, the director now owns 389,483 shares in the company, valued at approximately $977,602.33. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

MAIA Biotechnology Price Performance

Shares of MAIA opened at $3.06 on Wednesday. The stock has a market capitalization of $73.16 million, a P/E ratio of -1.90 and a beta of 0.32. MAIA Biotechnology, Inc. has a 52-week low of $0.82 and a 52-week high of $5.99.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.16. Equities research analysts expect that MAIA Biotechnology, Inc. will post -1.25 EPS for the current fiscal year.

Hedge Funds Weigh In On MAIA Biotechnology

Large investors have recently made changes to their positions in the business. Mather Group LLC. lifted its stake in MAIA Biotechnology by 50,150.0% during the second quarter. Mather Group LLC. now owns 12,060 shares of the company’s stock valued at $41,000 after buying an additional 12,036 shares in the last quarter. Ground Swell Capital LLC purchased a new stake in MAIA Biotechnology during the second quarter valued at about $56,000. Finally, Virtu Financial LLC purchased a new stake in MAIA Biotechnology during the first quarter valued at about $71,000. Institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.